je.st
news
Tag: study
Brazil unlikely to sustain gains in reducing deforestation without new incentives for ranchers, says study
2014-10-09 04:17:00| Climate Ark Climate Change & Global Warming Newsfeed
Mongabay: Cattle ranchers that drive the vast majority of forest clearing in the Brazilian Amazon are unlikely to be held at bay indefinitely unless they are afforded new incentives for keeping trees standing, argues new analysis published by an economic research group. The findings suggest that Brazil's recent progress in reducing deforestation - annual forest loss in the region has dropped by roughly 80 percent since 2004 - could easily be reversed. The study, which was carried out by Datu Research on behalf...
Tags: study
says
brazil
reducing
Floods Will Be Chronic Problem for East Coast Cities by 2030, Study Says
2014-10-08 20:02:00| Climate Ark Climate Change & Global Warming Newsfeed
Yale Environment 360: By 2030, residents of Washington, D.C., and Annapolis, Maryland, could be experiencing more than 150 tidal floods every year -- up from an average of just 50 today -- according to a recent study of sea level rise and coastal flood risk along the U.S. East Coast by the Union of Concerned Scientists. In another 15 years, that number could jump to 400 floods annually, the study says. A home purchased in some of the more flood-prone parts of those two cities could see daily flooding before a 30-year...
SBA Office Asks EPA To Pull Proposed Water Rule and Do Small-Business Impact Study
2014-10-08 17:32:42| ENR.com: Headline News
Comment period on controversial rule extended until Nov. 14.
Tags: office
study
water
impact
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
2014-10-08 17:13:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the companys investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting. The meeting is scheduled to take place at the John B. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
data
present
american
Pricing "critical" for producers as US chains up wine focus - study
2014-10-08 15:48:00| Daily beverage news and comment - from just-drinks.com
Pricing strategy is becoming a "critical skill" for wine producers in the US looking to penetrate the country's increasingly influential retail chains, according to a new report.
Tags: study
focus
critical
pricing
Sites : [603] [604] [605] [606] [607] [608] [609] [610] [611] [612] [613] [614] [615] [616] [617] [618] [619] [620] [621] [622] next »